nach oben

European Journal of Nuclear Medicine and Molecular Imaging

Erschienen in:

01.04.2006 | Original article

Cross-camera comparison of SPECT measurements of a 3-D anthropomorphic basal ganglia phantom

verfasst von: Walter Koch, Perry E Radau, Wolfgang Münzing, Klaus Tatsch

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 4/2006

Einloggen, um Zugang zu erhalten

Abstract

Purpose

SPECT examinations of neurotransmitter systems in the brain have to be comparable between centres to generate a comprehensive data pool, e.g. for multicentre studies. Equipment-specific effects on quantitative evaluations and corresponding methods for compensation, however, have been insufficiently examined. Previous studies have shown that quantitative results may vary significantly according to the imaging equipment used, thereby affecting clinical interpretation of the data. The aim of this study was to determine correction factors for common camera/collimator combinations based on standardised measurements of an anthropomorphic 3D basal ganglia phantom to compensate for the effects of different SPECT camera/collimator equipment. The latter may serve as a model for human studies of the dopaminergic system.

Methods

The striatum and background chambers of a commercially available phantom (RSD Alderson) were filled with various¹²³I concentrations encompassing specific striatum/background ratios from 0.6 to 16.1. This setup was imaged with the following four camera/collimator combinations: Siemens Multispect 3 fitted with LEHR and¹²³I parallel-hole collimators, Siemens ECAM with LEHR parallel-hole collimators and Philips Prism 3000 fitted with LEHR fanbeam collimators, using standardised protocols for acquisition and reconstruction. All scans were automatically co-registered to a SPECT template of the phantom and quantified using a 3D volume of interest (VOI) map based on a CT scan of the phantom. All striatal/background ratios calculated by SPECT were compared with the true ratios calculated from the measurements in a well counter. Regression analyses were performed and recovery correction factors between measured and true ratios determined.

Results

The relation between true and measured ratios could be sufficiently described by a linear regression for each camera/collimator combination without relevant improvement when using second-order polynomial regression models. The recovery correction factors and standard errors were 2.04±0.04 for the Philips Prism 3000, 2.67±0.03 for the Siemens Multispect 3/LEHR parallel-hole collimators, 2.15±0.03 for the Siemens Multispect 3/¹²³I collimators and 2.81±0.03 for the Siemens ECAM. Percentage recovery ranged from 36% to 49%.

Conclusion

Measurements of a 3D basal ganglia phantom with various imaging devices revealed linear correlations between measured and true striatal/background ratios. Based on these findings, adjustment of quantitative results between different equipment seems possible, provided that acquisition, reconstruction and evaluation are adequately standardised. The use of identical evaluation methods in phantom and patient studies (comparable shape, size and location of the VOIs) might allow transfer of the calculated correction factors from phantom to studies of the dopaminergic system in patients.

Bergmann H, Busemann-Sokole E, Horton PW. Quality assurance and harmonisation of nuclear medicine investigations in Europe. Eur J Nucl Med 1995;22:477–480PubMedCrossRef

Meyer PT, Sattler B, Lincke T, Seese A, Sabri O. Investigating dopaminergic neurotransmission with¹²³I-FP-CIT SPECT: comparability of modern SPECT systems. J Nucl Med 2003;44:839–845PubMed

Stodilka RZ, Kemp BJ, Prato FS, Nicholson RL. Importance of bone attenuation in brain SPECT quantification. J Nucl Med 1998;39:190–197PubMed

Tatsch K, Asenbaum S, Bartenstein P, Catafau A, Halldin C, Pilowsky LS, et al European Association of Nuclear Medicine procedure guidelines for brain neurotransmission SPET using¹²³I-labelled dopamine D₂ transporter ligands. Eur J Nucl Med Mol Imaging 2002;29:BP30–BP35PubMedCrossRef

Radau PE, Linke R, Slomka PJ, Tatsch K. Optimization of automated quantification of¹²³I-IBZM uptake in the striatum applied to parkinsonism. J Nucl Med 2000;41:220–227PubMed

Radau PE, Koch W, Holtmannspoetter M, Poepperl G, Tatsch K. Automated, objective software for 3D registration and analysis of dopamine transporter SPECT studies. J Nucl Med 2003;44:P12

Koch W, Radau PE, Hamann C, Tatsch K. Clinical testing of an optimized software solution for an automated, observer-independent evaluation of dopamine transporter SPECT studies. J Nucl Med 2005;46:1109–1118PubMed

Koch W, Münzing W, Geworski L, Sonnenschein W, Höffken H, Czech N, et al Zentrumübergreifende Messungen an einem Basalganglienphantom zur Vereinheitlichung der SPECT Diagnostik des dopaminergen Systems. In: Brink I, editor. Nuklearmedizin als Paradigma molekularer Bildgebung. Berlin, Germany: Blackwell; 2002. p. 20

Hudson H, Larkin RS. Accelerated image reconstruction using ordered subsets of projection data. IEEE Trans Med Imaging 1994;13:594–600CrossRef

10.

Kauppinen T, Yang J, Kilpelainen H, Kuikka JT. Quantitation of neuroreceptors: a need for better SPECT imaging. Nuklearmedizin 2001;40:102–106PubMed

11.

Booij J, Hemelaar TG, Speelman JD, de Bruin K, Janssen AG, van Royen EA. One-day protocol for imaging of the nigrostriatal dopaminergic pathway in Parkinson’s disease by [¹²³I]FPCIT SPECT. J Nucl Med 1999;40:753–761PubMed

12.

Pirker W, Asenbaum S, Hauk M, Kandlhofer S, Tauscher J, Willeit M, et al Imaging serotonin and dopamine transporters with¹²³I-beta-CIT SPECT: binding kinetics and effects of normal aging. J Nucl Med 2000;41:36–44PubMed

13.

Brucke T, Kornhuber J, Angelberger P, Asenbaum S, Frassine H, Podreka I, et al SPECT imaging of dopamine and serotonin transporters with [¹²³I]beta-CIT. Binding kinetics in the human brain. Imaging serotonin and dopamine transporters with¹²³I-beta-CIT SPECT: binding kinetics and effects of normal aging. J Neural Transm Gen Sect 1993;94:137–146PubMedCrossRef

14.

Geworski L, Knoop BO, de Cabrejas ML, Knapp WH, Munz DL. Recovery correction for quantitation in emission tomography: a feasibility study. Eur J Nucl Med 2000;27:161–169PubMedCrossRef

15.

Tatsch K, Asenbaum S, Bartenstein P, Catafau A, Halldin C, Pilowsky LS, et al European Association of Nuclear medicine procedure guidelines for brain neurotransmission SPET using¹²³I-labelled dopamine D₂ receptor ligands. Eur J Nucl Med Mol Imaging 2002;29:BP23–BP29PubMedCrossRef

16.

Hamann C, Koch W, Radau PE, Tatsch K. Iterative reconstruction or filtered backprojection for quantitative assessment of dopamine d2 receptor studies? J Nucl Med 2003;44:114P

17.

Hashimoto J, Kubo A, Ogawa K, Amano T, Fukuuchi Y, Motomura N, et al Scatter and attenuation correction in technetium-99m brain SPECT. J Nucl Med 1997;38:157–162PubMed

18.

Hashimoto J, Sasaki T, Ogawa K, Kubo A, Motomura N, Ichihara T, et al Effects of scatter and attenuation correction on quantitative analysis of beta-CIT brain SPET. Nucl Med Commun 1999;20:159–165PubMedCrossRef

19.

Soret M, Koulibaly PM, Darcourt J, Hapdey S, Buvat I. Quantitative accuracy of dopaminergic neurotransmission imaging with¹²³I SPECT. J Nucl Med 2003;44:1184–1193PubMed

20.

Yang J, Kuikka JT, Vanninen E, Kauppinen T, Lansimies E, Patomaki L. Evaluation of scatter correction using a single isotope for simultaneous emission and transmission data. Phantom and clinical patient studies. Nuklearmedizin 1999;38:49–55PubMed

21.

Kauppinen T, Koskinen MO, Alenius S, Vanninen E, Kuikka JT. Improvement of brain perfusion SPET using iterative reconstruction with scatter and non-uniform attenuation correction. Eur J Nucl Med 2000;27:1380–1386PubMedCrossRef

22.

Ichihara T, Ogawa K, Motomura N, Kubo A, Hashimoto S. Compton scatter compensation using the triple-energy window method for single- and dual-isotope SPECT. J Nucl Med 1993;34:2216–2221PubMed

23.

El Fakhri G, Buvat I, Benali H, Todd-Pokropek A, Di Paola R. Relative impact of scatter, collimator response, attenuation, and finite spatial resolution corrections in cardiac SPECT. J Nucl Med 2000;41:1400–1408PubMed

24.

Yanch JC, Flower MA, Webb S. Improved quantification of radionuclide uptake using deconvolution and windowed subtraction techniques for scatter compensation in single photon emission computed tomography. Med Phys 1990;17:1011–1022PubMedCrossRef

25.

Jaszczak RJ, Greer KL, Floyd CE Jr, Harris CC, Coleman RE. Improved SPECT quantification using compensation for scattered photons. J Nucl Med 1984;25:893–900PubMed

26.

El Fakhri G, Moore SC, Maksud P, Aurengo A, Kijewski MF. Absolute activity quantitation in simultaneous¹²³I/^99mTc brain SPECT. J Nucl Med 2001;42:300–308PubMed

27.

Linke R, Gostomzyk J, Hahn K, Tatsch K. [¹²³I]IPT binding to the presynaptic dopamine transporter: variation of intra- and interobserver data evaluation in parkinsonian patients and controls. Eur J Nucl Med 2000;27:1809–1812PubMedCrossRef

28.

Hamann C, Koch W, Radau PE, Tatsch K. Automated evaluation of dopamine D2 receptor SPECT studies: Benefit in clinical routine? J Nucl Med 2003;44:P261–P262

Titel: Cross-camera comparison of SPECT measurements of a 3-D anthropomorphic basal ganglia phantom
verfasst von: Walter Koch
Perry E Radau
Wolfgang Münzing
Klaus Tatsch
Publikationsdatum: 01.04.2006
Verlag: Springer-Verlag
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 4/2006
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-005-0036-8

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2006

Role of pre-operative imaging using 99mTc-MIBI and neck ultrasound in patients with secondary hyperparathyroidism who are candidates for subtotal parathyroidectomy

Synthesis of 99mTc-HYNIC-interleukin-12, a new specific radiopharmaceutical for imaging T lymphocytes

PET/MRI depicts the exact location of meniscal tear associated with synovitis

PET imaging of brain astrocytoma with 1-11C-acetate

Multi-tracer small animal PET imaging of the tumour response to the novel pan-Erb-B inhibitor CI-1033

No-carrier-added versus carrier-added123I-metaiodobenzylguanidine for the assessment of cardiac sympathetic nerve activity